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ABSTRACT
Engraftment syndrome (ES) encompasses a constellation of symptoms that occur during neutrophil recovery
after both autologous and allogeneic hematopoietic stem cell transplantation (HCT). Although it is well
characterized after conventional myeloablative procedures, limited data exist on this complication after
nonmyeloablative allogeneic HCT. The clinical manifestations, incidence, and risk factors associated with ES
were investigated in a consecutive series of patients undergoing cyclophosphamide/fludarabine-based nonmy-
eloablative allogeneic HCT from a related HLA-compatible donor. Fifteen (10%) of 149 patients (median age,
53 years; range, 27-66 years) developed ES; the onset of symptoms occurred at a median of 10 days (range, 3-14
days), and they consisted of fever (100%), cough (53%), diffuse pulmonary infiltrates (100%), rash (13%), and
room air hypoxia (87%). ES was more likely to develop in patients who received empiric amphotericin
formulations after transplant conditioning (Fisher exact test; P  .007). In a multivariate analysis, older patient
age, female sex, and treatment with amphotericin were predictors for the development of ES. Intravenous
methylprednisolone led to the rapid resolution of ES; however, transplant-related mortality was significantly
higher (cumulative incidence, 49% versus 16%; P  .0005), and median survival was significantly shorter (168
versus 418 days; P  .005) in patients with ES compared with non-ES patients. In conclusion, ES occurs
commonly after cyclophosphamide/fludarabine-based nonmyeloablative transplantation and responds rapidly
to corticosteroid treatment, but it is associated with a higher risk of nonrelapse mortality and with shorter
overall survival.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Myeloablative allogeneic hematopoietic cell trans-
lantation (HCT) can cure a variety of advanced he-
atologic malignancies. Unfortunately, toxicities as-
ociated with high-dose conditioning regimens
ontribute substantially to transplant-related morbid-
ty and mortality and limit conventional HCT to rel-
tively younger and healthier patients. Recently, in-
estigators have demonstrated that graft-versus-tumor
ffects after nonmyeloablative HCT can cure chemo- c
42herapy-resistant hematologic malignancies. It is im-
ortant to note that reductions in the intensity of the
reparative regimen reduce conditioning-related tox-
cities, thus allowing this transplantation approach to
e applied to older patients or to those with medical
omorbidities. Although randomized trials have yet to
e performed, transplant-related mortality (TRM)
eems to be reduced with nonmyeloablative transplan-
ations compared with historical controls treated with
onventional myeloablative HCT [1].
t
p
H
u
l
d
5
c
t
a
e
n
p
T
p
m
c
d
g
o
(
i
e
m
t
t
r
[
t
i
I
t
b
b
f
a
M
d
g
I
c
n
a
p
c
[
t
i
c
t
c
b
i

(
A
f
H
t
k
r
m
b
g
k
d
v
d
(
m
o
r
i
w
f
P
p
s
D
m
[
m
t
c
w
g
w
m
b
p
e
r
b
t
l
o
r
(
e
v
p
o
a
Engraftment Syndrome after Nonmyeloablative Allogeneic HCT
BEngraftment syndrome (ES) involves a constella-
ion of signs and symptoms that occur during neutro-
hil recovery after both autologous and allogeneic
CT. Differences in the intensity and types of agents
sed in myeloablative conditioning regimens and the
ack of a standard deﬁnition likely account for the high
egree of variability in the reported incidence (5%-
9%) of this complication [2-16]. Although the clini-
al ﬁndings associated with ES vary among reports,
hey consistently include skin rash, fever, weight gain,
nd the development of noncardiogenic pulmonary
dema associated with respiratory distress and hypoxia
ot attributable to any known causes such as infection,
ulmonary embolism, or hemorrhage [7-12,16-19].
he pathophysiology of ES is poorly understood;
roinﬂammatory cytokines such as interleukin 1, tu-
or necrosis factor , and interferon , released as a
onsequence of tissue injury from dose-intensive con-
itioning or from recovering neutrophils during en-
raftment, have been hypothesized to play a role [19].
Although several conditioning-related toxicities
ccur less often after reduced-intensity conditioning
eg, severe mucositis, veno-occlusive disease, and id-
opathic pneumonia syndrome), relatively few data
xist on the incidence and severity of ES after non-
yeloablative transplantation [20]. Reducing the in-
ensity of transplantation conditioning results in less
issue damage and decreases inﬂammatory cytokine
elease compared with myeloablative transplantation
21]. On the basis of the proposed pathophysiology of
his syndrome, we hypothesized that ES would occur
nfrequently with nonmyeloablative transplantations.
n contrast, we observed a relatively high incidence of
his complication in patients undergoing nonmyeloa-
lative HCT after cyclophosphamide/ﬂudarabine-
ased conditioning. The clinical manifestations, risk
actors, and outcomes in patients who developed ES
fter nonmyeloablative HCT are described herein.
ATERIALS AND METHODS
One hundred forty-nine consecutive patients un-
erwent a cyclophosphamide/ﬂudarabine-based allo-
eneic HCT on National Heart, Lung and Blood
nstitute Institutional Review Board–approved proto-
ols investigating nonmyeloablative transplantation in
onmalignant hematologic disorders (severe aplastic
nemia, paroxysmal nocturnal hemoglobinuria, and
ure red cell aplasia; n  15), hematologic malignan-
ies (n  38), and metastatic solid tumors (n  96)
22]. Patients were required to have a pretransplanta-
ion chest radiograph to exclude an active pulmonary
nfection, a pretransplantation echocardiogram to ex-
lude cardiac failure, and baseline pulmonary function
esting to ensure adequate lung function (ie, diffusing
apacity for carbon monoxide [corrected for hemoglo- n
B&MTin] 65%). The preparative regimen consisted of
ntravenous cyclophosphamide (60 mg/kg/d) on days
7 and 6, followed by intravenous ﬂudarabine
25 mg/m2/d) on days 5, 4, 3, 2, and 1.
n unmanipulated granulocyte colony-stimulating
actor–mobilized allograft from a related 6/6 or 5/6
LA antigen–matched donor was infused on day 0;
he target CD34 cell dose was 5  106 cells per
ilogram of recipient weight. Seventeen patients who
eceived an allograft from a 5/6 HLA antigen–
atched donor or who had a history of signiﬁcant red
lood cell or platelet transfusions had antithymocyte
lobulin added to the conditioning regimen (40 mg/
g/d on days5 to2). All patients received standard
oses of oral ﬂuconazole and acyclovir as fungal and
iral prophylaxis. Cyclosporine for graft-versus-host
isease (GVHD) prophylaxis was given either alone
n  66) or combined with either mycophenolate
ofetil (n  78) or low-dose methotrexate (5 mg/m2
n days 1, 3, and 6; n  5). None of the patients
eceived granulocyte colony-stimulating factor after
nfusion of the allograft. Blood was obtained for
eekly cytomegalovirus (CMV) antigenemia testing
rom engraftment until posttransplantation day 100.
atients who developed CMV antigenemia received
reemptive therapy with ganciclovir or foscarnet at
tandard induction doses to prevent CMV disease.
iagnosis and Management of ES
We deﬁned ES by using the diagnostic criteria
ost commonly reported from prior publications
2-15,19], which included the development of 2 or
ore of the following symptoms within 96 hours of
he start of neutrophil recovery (absolute neutrophil
ount [ANC] 100): (1) fever (temperature 38.5°C)
ithout an identiﬁable infectious cause; (2) weight
ain 2.5% over the pretransplantation baseline
eight; (3) erythematous rash not attributable to a
edication; and (4) hypoxia, pulmonary inﬁltrates, or
oth not attributable to infection, thromboembolism,
ulmonary hemorrhage, ﬂuid overload, or cardiac dis-
ase. An infectious etiology of fever, hypoxia, and
espiratory distress was ruled out in all ES cases by
lood, urine, and sputum cultures; CMV antigenemia
esting; and bronchoalveolar lavage. Bronchoalveolar
avage samples were sent for cytopathology (to rule
ut viral cytopathic changes) and cultured for bacte-
ial, fungal, and common respiratory viral pathogens
shell vial cultures for CMV, parainﬂuenza 1-3, inﬂu-
nza A and B, respiratory syncytial virus, and adeno-
irus). Because of the low diagnostic yield and risk of
rocedure-associated morbidity, open lung biopsies
n patients developing ES were not performed. After
diagnosis of ES, patients were treated with intrave-
ous methylprednisolone 1 to 3 mg/kg/d. Once symp-
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5oms improved, corticosteroids were typically tapered
ver 2 to 3 weeks.
tatistical Methods
An analysis of factors associated with the develop-
ent of ES was performed. Pretransplantation vari-
bles analyzed included patient age and sex, underly-
ng diagnosis, previous treatment (including
hemotherapy and prior HCT), smoking history, his-
ory of thoracic radiation, and baseline pulmonary
unction tests. Transplant-related variables included
onor sex, ABO blood group compatibility, CD34
nd CD3 cell dose, GVHD prophylactic regimen,
evelopment and grade of acute GVHD, and use of
mphotericin formulations.
Comparisons between patients with ES and those
ithout were made by using the Wilcoxon test for
ontinuous variables and either a 2 test or Fisher
xact test for categorical variables [23]. Survival was
stimated by the Kaplan-Meier method, and differ-
nces were assessed by using both the Gehan-Wil-
oxon test and the log-rank test [23,24]. Because ES
eveloped by day 14, all time-to-event comparisons
ere made from day 14 after transplantation, although
ummary statistics (eg, medians) are reported from the
ime of transplantation. This eliminated 2 patients
ho did not have ES from the analysis because of early
eath. Time to grades II to IV and III to IV acute
VHD and TRM were estimated by using cumulative
ncidence methods; death was considered a competing
isk [25]. Comparisons between estimates of cumula-
ive incidence functions were made by using the 2
est proposed by Gray [26]. Logistic regression was
erformed to model the probability of ES based on
ariables occurring before the development of ES
23]. Both ordinary logistic regression and penalized
ikelihood logistic regression, which reduces the bias
n coefﬁcient estimates due to the small number of
vents, were used [24,27]. The 2 sets of results were
ery similar, and the penalized logistic regression re-
ults (with coefﬁcients closer to 0) are reported.
ESULTS
One hundred forty-nine consecutive patients re-
eived a nonmyeloablative allogeneic HCT from an
LA-identical (n  144) or single HLA antigen–
ismatched (n  5) related donor. Fifteen patients
10%; median age, 53 years; range, 27-66 years) de-
eloped ES (Table 1); two thirds with this complica-
ion had a solid tumor as an underlying diagnosis (6
enal cell carcinoma, 2 melanoma, 1 pancreatic cancer,
nd 1 hepatocellular carcinoma), and the remainder
ad a diagnosis of either a hematologic malignancy (1
hronic lymphocytic leukemia, 1 chronic myeloge-
ous leukemia, and 2 myelodysplastic syndromes) or a
44T
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Engraftment Syndrome after Nonmyeloablative Allogeneic HCT
Bone marrow failure syndrome (1 paroxysmal noctur-
al hemoglobinuria). The onset of ES symptoms oc-
urred at a median of 10 days (range, 3-14 days); the
edian ANC at the onset of symptoms was 376 cells
er microliter (range, 6-4675 cells per microliter).
atients presented with fever (100%), room air hyp-
xia (87%; mean room air oxygen saturation, 89%;
ange, 78%-93%), diffuse pulmonary inﬁltrates
100%; observed by chest radiograph or computerized
omography scan), cough (53%), wheezing (26%), and
eight gain (53%; deﬁned as an increase of body
eight 2.5% above admission baseline); only a mi-
ority (13%) had an associated skin rash.
Univariate comparisons of patient characteristics
nd risk factors for the development of ES are shown
n Table 2. Patients with ES were signiﬁcantly older
median, 53 years) than patients without ES (median,
7 years; P .026). ES was signiﬁcantly more likely to
evelop in patients who received empiric amphoteri-
in formulations after transplantation (between post-
ransplantation days 0 and 14; Fisher exact test; P 
007). Twenty-seven (18%) of 149 patients were re-
eiving amphotericin formulations before the devel-
pment of ES. Five patients (1 ES patient and 4
on-ES patients) with a history of an invasive fungal
nfection treated successfully before transplantation
eceived amphotericin preparations instead of ﬂucon-
zole as fungal prophylaxis. The remaining 22 patients
6 ES and 16 non-ES) received amphotericin as em-
iric treatment (ie, no infectious pathogen identiﬁed)
or neutropenic fever that persisted longer than 72
able 2. Univariate Comparisons of Patients with and without Engraf
Variable
edian age, y (range) 5
ale 9/1
obacco use 4/1
iagnosis
Solid tumor 10/1
Hematologic malignancy, PNH, or SAA 5/1
edian FEV1/FVC
edian DLCOc (% predicted)
edian TLC (% predicted)
edian number of prior therapies (range)
rior chest radiation 5/1
rior fludarabine 0/1
VHD prophylaxis
CSA 8/1
CSA  MMF 6/1
CSA  MTX 1/1
edian CD34 dose, 106/kg (range) 8.2
edian CD3 dose, 107/kg (range) 3.6
edian number of days to ANC > 100 (range) 1
edian number of days to ANC > 500 (range) 1
mphotericin use before engraftment* 7/1
NH indicates paroxysmal nocturnal hemoglobinuria; SAA, severe
vital capacity; DLCOc , diffusion capacity for carbon monoxide
MMF, mycophenolate mofetil; MTX, methotrexate.
Three received amphotericin deoxycholate, and 4 received lipid foours after the initiation of empiric antibiotic therapy. m
B&MThere was no signiﬁcant difference between groups in
he type of amphotericin formulation used (lipid ver-
us nonlipid formulation) or the indication for anti-
ungal coverage (prophylaxis versus treatment). No
igniﬁcant difference was observed between groups in
rior tobacco use, prior therapy with nucleoside ana-
ogues, number of prior chemotherapy regimens,
rior chest radiation therapy, baseline pulmonary
unction (forced expiratory volume in 1 second/forced
ital capacity, diffusing capacity for carbon monoxide
corrected for hemoglobin], and total lung capacity),
umor histology, CD34 and CD3 transplant doses,
VHD prophylactic regimen (cyclosporine alone, cy-
losporine plus mycophenolate mofetil, or cyclospor-
ne plus methotrexate), or change in baseline weight to
eight during engraftment (ANC  500). None of
he patients who developed ES had a pretransplanta-
ion history of pulmonary edema, pneumonia, or non-
nfectious pneumonitis syndrome. The median time
rom transplantation to an ANC of 100 cells per
icroliter and an ANC of 500 cells per microliter
as 9 and 10 days (P  .20) and 11 and 11 days (P 
39) for ES and non-ES patients, respectively. ES was
ot associated with graft rejection. Donor myeloid
nd T-cell engraftment proﬁles were similar between
roups (data not shown).
Pulmonary and other symptoms related to ES
mproved rapidly after the initiation of corticosteroid
herapy; 14 (93%) of 15 patients were treated with
ntravenous methylprednisolone (1-3 mg/kg/d),
hereas 1 patient with rapidly growing metastatic
yndrome (ES)
15) No ES (n  134) P Value
66) 47 (14-71) .026
) 100/134 (67%) .23
) 43/134 (32%) .78
.82
) 82/134 (64%)
) 52/134 (36%)
0 1.041 .34
6 92.2 .76
2 91.9 .61
) 2 (0-7) .17
) 39/134 (29%) .77
9/134 (7%) .60
.32
) 58/134 (43%)
) 72/134 (54%)
4/134 (3%)
-21.06) 7.39 (1.91-30.0) .34
-7.10) 3.52 (0.88-16.0) .69
3) 9 (4-16) .20
5) 11 (6-21) .39
) 20/134 (15%) .007
anemia; FEV1/FVC, forced expiratory volume at 1 second/forced
ted for hemoglobin); TLC, total lung capacity; CSA, cyclosporine;
ions of amphotericin.tment S
ES (n 
3 (27-
5 (60%
5 (27%
5 (67%
5 (33%
1.
92.
88.
1 (0-6
5 (33%
5 (0%)
5 (53%
5 (40%
5 (7%)
0 (5.10
2 (1.10
0 (6-1
1 (7-1
5 (47%
aplastic
(correcelanoma died from disease progression without re-
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5eiving steroid therapy. Steroid therapy was initiated
4, 48, 72, 96, and 120 hours after the onset of ES
ymptoms in 8 (57%) of 14, 3 (21%) of 14, 1 (7%) of
4, 1 (7%) of 14, and 1 (7%) of 14 patients, respec-
ively. The median time from the initiation of steroid
herapy to symptomatic pulmonary improvement was
day (range, 1-4 days), and symptoms related to ES
esolved completely in all patients within 2 weeks of
orticosteroid therapy initiation. After an improve-
ent in symptoms associated with ES, the steroid
ose was initially decreased by 50% in most patients,
ollowed by a 15% to 20% reduction in steroid dose
very 4 to 6 days thereafter. Although no patients
equired mechanical ventilation for respiratory failure,
ost received supplemental oxygen via nasal canula or
ace mask for room air hypoxia (ie, oxygen saturation
90%).
Although corticosteroid therapy resulted in rapid
mprovement of symptoms, TRM was signiﬁcantly
igher (Figure 1) in ES patients compared with
on-ES patients (49% versus 16%, respectively; P 
005). Culture-negative sepsis (n  3) or uncontrolled
ystemic infection (n  3) was the cause of death in 6
f 7 patients who died from TRM (Table 1). Among
he 7 patients with ES who died from TRM, the
edian time from the onset of ES symptoms to death
as 57 days (range, 6-220 days). ES was also associated
ith reduced early survival (Figure 2); median survival
as signiﬁcantly shorter in ES patients (168 days)
ompared with non-ES patients (418 days; Gehan-
ilcoxon test; P  .005). At day 100, 53% of patients
ith ES were alive, compared with 91% without ES.
he causes of death among ES patients included
VHD (n 1), systemic infection or culture-negative
epsis (n  6), and progressive disease (n  3); 5 ES
atients were alive at last follow-up (Table 1). The
ime to acute GVHD grades II to IV, acute GVHD
igure 1. Cumulative incidence of treatment-related mortality
TRM) from day 14 after transplantation. A signiﬁcantly higher
ercentage of patients who developed engraftment syndrome (49%)
ied from TRM compared with non–engraftment syndrome pa-1ients (16%; P  .0005).
46rades III and IV, and death from GVHD did not
iffer signiﬁcantly for ES patients compared with
on-ES patients (Figure 3). In logistic regression, pa-
ient age, sex, prior amphotericin treatment, disease,
D3 cell dose, CD34 cell dose, and their loga-
ithms were considered as prognostic factors. Older
atient age (P  .04), amphotericin use before day 14
fter transplantation (P  .0029), and female sex (P 
02) were found to be predictors for the development
f ES (Figure 4). Because the number of cases of ES
as small in our series, these prognostic factors should
e conﬁrmed by others.
ISCUSSION
Reducing the intensity of transplantation condition-
ng has been shown to decrease a variety of complica-
ions associated with allogeneic HCT. As a consequence,
onmyeloablative transplantation approaches are in-
reasingly being used to treat older or debilitated pa-
ients in whom a high risk of regimen-related mortality
recludes conventional HCT. Although several studies
ave reported a reduction in a variety of transplant-
elated morbidities, surprisingly few data exist on ES and
ther pulmonary complications associated with this
ewer transplantation strategy [8]. Because tissue dam-
ge from myeloablative conditioning is thought to
lay a critical role in the development of complica-
ions such as diffuse alveolar hemorrhage, ES, or id-
opathic pneumonia syndrome, one might hypothesize
hat these pulmonary complications would occur in-
requently after nonmyeloablative conditioning. In-
eed, a recent retrospective analysis from the Fred
utchinson Cancer Center reported a lower inci-
ence of idiopathic pneumonia syndrome (deﬁned as
oninfectious interstitial pneumonitis occurring up to
igure 2. Survival from 14 days after transplantation. The median
urvival for engraftment syndrome (ES) patients was signiﬁcantly
horter (168 days) compared with non-ES patients (418 days; P 
005; Gehan-Wilcoxon test). GP indicates group.20 days after transplantation) after low-dose total
F
A
p
Engraftment Syndrome after Nonmyeloablative Allogeneic HCT
Bigure 3. A, Cumulative incidence of grades II to IV acute graft-versus-host disease (AGVHD). B, Cumulative incidence of grades III and IV
GVHD. C, Cumulative incidence of death from AGVHD. The differences between the engraftment syndrome (ES) patients and non-ES
atients were not signiﬁcantly different.
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5ody irradiation–based conditioning than after my-
loablative transplantation [20].
This is the ﬁrst published analysis to investigate
he incidence, risk factors, and outcome associated
ith the development of ES in patients undergoing
onmyeloablative allogeneic HCT. Although this cy-
lophosphamide/ﬂudarabine-based regimen was gen-
rally well tolerated and spared patients from condi-
ioning-related toxicities such as mucositis (0/149) and
epatic veno-occlusive disease (1/149), 10% devel-
ped ES that presented as acute onset hypoxia, fever,
nd noninfectious pulmonary inﬁltrates coincident
ith neutrophil recovery.
As observed by others [20], symptoms related to
S (including fever, respiratory distress, and hypoxia)
mproved quickly with the use of corticosteroid ther-
py. Nevertheless, patients with this complication had
signiﬁcantly higher risk of TRM and a signiﬁcantly
ower overall survival. A reduction in survival and an
ncreased incidence of TRM in patients who devel-
ped ES after myeloablative conditioning has previ-
usly been reported [5,12]. A recent multivariate anal-
sis of children undergoing autologous transplantation
or malignant diseases revealed ES to be the major con-
ributor to TRM [28]. In our series, death from TRM
ccurred primarily as a consequence of systemic in-
ection or culture-negative sepsis, in most cases after
ll symptoms related to ES had resolved and cortico-
teroid therapy had been discontinued. The immuno-
uppressive effects of corticosteroid therapy may have
ontributed to the ES cohort having an increase in
nfection-related mortality. Alternatively, patients
ho developed ES may have altered immune function
efore the initiation of steroid therapy that might
redispose to the development of opportunistic infec-
ions.
Older patient age is an independent risk factor for
RM, even with the use of nonmyeloablative condi-
ioning [29]. The older age of ES patients may in part
ccount for their increased incidence of TRM. How-
ver, it is possible that patients who developed ES
ave biologic differences that predispose to other
orbidities associated with allogeneic transplantation.
peciﬁc genetic polymorphisms have previously been
Figure 4. Logistic model tohown to protect against or predispose to the devel- a
48pment of acute GVHD [30-33]. Although further
tudy in this area is needed, it is possible that poly-
orphisms in genes that encode proinﬂammatory cy-
okines might also predispose to other transplant-
ssociated morbidities, such as ES.
Several factors have been associated with the de-
elopment of ES after dose-intensive conditioning
2,3,5,7,10,11,13,15-17]. Our observation that older
atient age, female sex, and amphotericin use are
trongly associated with the development of ES after
onmyeloablative conditioning is consistent with sim-
lar ﬁndings in patients undergoing myeloablative
CT [4,7,10,13].
Life-threatening noninfectious pulmonary injury
as previously been reported with amphotericin use
34-36]. Pulmonary endothelial damage, increased
eutrophil aggregation, and increased tumor necrosis
actor  production could potentially mediate ampho-
ericin-induced pulmonary injury [37-40]. The early
nd brisk autologous neutrophil recovery that oc-
urred with this nonmyeloablative regimen might
ave ampliﬁed amphotericin-induced lung injury by
echanisms analogous to those that cause pulmonary
oxicity when granulocyte transfusions are combined
ith amphotericin preparations. Furthermore, am-
hotericin deoxycholate has been shown to increase
evels of proinﬂammatory cytokine gene and protein
xpression in immune cells [41]. Whether the incor-
oration of newer, non–amphotericin-based antifun-
al agents (eg, voriconazole and caspofungin) as em-
iric therapy for febrile neutropenia will decrease the
ncidence of ES is currently being investigated. Fi-
ally, it is important to consider that amphotericin use
ay have served as a surrogate marker for those who
ere more ill, perhaps accounting at least in part for
he reduced survival observed in the ES cohort.
In contrast to studies with myeloablative trans-
lantations, we found no relationship between the
ype of underlying malignancy, GVHD prophylactic
egimen, prior chest radiation, CD34 cell dose, or
arly neutrophil engraftment on the development of
S. Fludarabine has been reported to cause steroid-
esponsive pulmonary toxicity in a small percentage of
atients who have received prior treatment with this
t probability of ES, P(ES).gent [42]. In this series, all patients were treated with
ﬂ
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Budarabine as part of the nonmyeloablative prepara-
ive regimen; however, because none who developed
S had received prior therapy with ﬂudarabine (Table
), it is less likely this agent played a direct role in this
omplication.
Several reports have implicated early-onset
VHD as being associated with the development of
S after myeloablative conditioning [2,15,16]. Acute
VHD is a time-dependent variable; in our series, ES
ccurred early (median, 10 days) and always preceded
he development of acute GVHD. Therefore, in our
ultivariate analysis of factors associated with devel-
pment of ES, we were able to consider only factors
hat preceded ES onset. We found that the incidence
f acute GVHD and the cumulative incidence of
eath from acute GVHD did not differ between ES
nd non-ES patients, although the power to detect
uch a difference was not high. It is important to note
hat graft rejection has also been reported to be asso-
iated with a high incidence of ES after an antithy-
ocyte globulin/thymic irradiation–based nonmy-
loablative transplantation approach [8]. This is in
ontrast to our cyclophosphamide/ﬂudarabine-based
egimen, in which sustained donor engraftment oc-
urred in all patients who developed ES.
Finally, in contrast to other nonmyeloablative
ransplantation strategies, all patients treated with our
yclophosphamide/ﬂudarabine-based regimen devel-
ped severe neutropenia (ie, ANC 	100 cells per
icroliter). The observation that ES occurred despite
he use of a nonmyeloablative regimen that spared
atients from conditioning-associated toxicities such
s mucositis and veno-occlusive disease implies that
eutrophils and/or soluble factors released during the
eutrophil recovery phase play a role equal to, if not
reater than, that of conditioning-induced tissue dam-
ge in the pathophysiology of ES. Therefore, it is
ikely that differences in nonmyeloablative regimens
hat affect the development, depth, and duration of
eutropenia will also affect the incidence of this com-
lication. Because ES occurs during neutrophil recov-
ry, one might anticipate that this complication would
ccur less often with nonmyeloablative regimens that
re associated with a lower incidence of neutropenia.
n this, as in other analyses, a diagnosis of ES was
ade on the basis of the development of symptoms
both pulmonary and nonpulmonary) during a rela-
ively brief window of neutrophil recovery (ie, within
6 hours of the neutrophil count recovering to 100
ells per microliter). Because idiopathic pneumonia
yndrome has been deﬁned as acute, noninfectious,
iffuse lung injury that occurs after bone marrow
ransplantation, some overlap in diagnosis may occur.
owever, unlike ES, idiopathic pneumonia syndrome
an occur up to 4 months after transplantation, is not
learly associated with neutrophil recovery, is usually
nresponsive to corticosteroid therapy, and typically
B&MTas a more malignant clinical course characterized by
ulminant pulmonary failure and death. In contrast,
he rapid improvement in symptoms associated with
S after corticosteroid therapy further suggests a dis-
inct pathophysiology between these processes.
In conclusion, we observed a high incidence of ES
n patients undergoing allogeneic HCT after cyclo-
hosphamide/ﬂudarabine-based conditioning. Pa-
ients who are older, who are female, or who have
eceived amphotericin-based formulations seem to be
t increased risk for this complication. Although cor-
icosteroids rapidly improved symptoms, patients who
eveloped ES after nonmyeloablative transplantation
eemed to have an increased risk of TRM and a re-
uced overall survival.
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